Study of PK/PD parameters for vancomycin in elderly patients aged over 75 Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues Year: 2015
Clinical efficacy of moxifloxacin in severely ill patients with CAP Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Single-dose, first-in-human study of AMG 317: safety and pharmacokinetics in healthy and asthmatic adults Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Pharmacokinetic (PK) and pharmacodynamic (PD) data for inhaled and intranasal corticosteroids (CS) reassessed using a physiological PK/PD model Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Multiple-dose study of AMG 317 in adults with asthma: pharmacokinetics and safety Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Pharmacokinetics (PK) and pharmacodynamics (PD) of tetomilast in stable COPD subjects Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
Population pharmacokinetics and pharmacodynamics of GSK961081 (MABA) in patients with moderate to severe COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Clinical use of ibuprofen in CF children Source: ISSN=ISSN 1810-6838, ISBN=, page=281 Year: 2008
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Feasibility and safety evaluation of Simeox airway clearance technique (ACT) in patients with bronchiectasis Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019
Efficacy and safety of bronchoscopy in the elderly Source: Eur Respir J 2004; 24: Suppl. 48, 70s Year: 2004
Diagnostic yield and safety of flexible bronchoscopy for the diagnosis of pulmonary infections in patients with and without haematological malignancies Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019
Single-dose, first-in-human study of AMG 853: Pharmacokinetics, pharmacodynamics, and safety in healthy adults Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
The pharmacokinetic of the main oral antibiotics in children with cystic fibrosis. Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019
Relationship between omalizumab pharmacokinetics (PK), IgE pharmacodynamics (PD) and clinical symptoms in patients with severe persistent allergic asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008